BLACKROCK HEALTH SCIENCES (BME) Fundamental Analysis & Valuation

NYSE:BME • US09250W1071

40.73 USD
-0.52 (-1.26%)
Last: Mar 9, 2026, 01:42 PM
Overview Stock Chart Technical Analysis News

This BME fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BME. BME was compared to 0 industry peers in the Unkown industry. Both the profitability and financial health of BME have multiple concerns. BME does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. BME Profitability Analysis

1.1 Basic Checks

  • In the past year BME has reported negative net income.
  • In the past year BME had a positive cash flow from operations.
  • Of the past 5 years BME 4 years were profitable.
  • The reported operating cash flow has been mixed in the past 5 years: BME reported negative operating cash flow in multiple years.
BME Yearly Net Income VS EBIT VS OCF VS FCFBME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

1.2 Ratios

Industry RankSector Rank
ROA -4.83%
ROE -5.03%
ROIC 0.16%
ROA(3y)1.06%
ROA(5y)5.33%
ROE(3y)1.07%
ROE(5y)5.44%
ROIC(3y)0.2%
ROIC(5y)0.12%
BME Yearly ROA, ROE, ROICBME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15

1.3 Margins

  • In the last couple of years the Profit Margin of BME has declined.
  • BME's Operating Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 13.92%
PM (TTM) N/A
GM 100%
OM growth 3Y169.88%
OM growth 5Y-0.74%
PM growth 3Y-30.97%
PM growth 5Y-28.42%
GM growth 3YN/A
GM growth 5YN/A
BME Yearly Profit, Operating, Gross MarginsBME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BME Health Analysis

2.1 Basic Checks

  • BME has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, BME has more shares outstanding
  • The debt/assets ratio for BME is higher compared to a year ago.
BME Yearly Shares OutstandingBME Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
BME Yearly Total Debt VS Total AssetsBME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 15.59 indicates that BME is not in any danger for bankruptcy at the moment.
  • The Debt to FCF ratio of BME is 0.02, which is an excellent value as it means it would take BME, only 0.02 years of fcf income to pay off all of its debts.
  • BME has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • Although BME's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.02
Altman-Z 15.59
ROIC/WACCN/A
WACCN/A
BME Yearly LT Debt VS Equity VS FCFBME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 0.10 indicates that BME may have some problems paying its short term obligations.
  • BME has a Quick Ratio of 0.10. This is a bad value and indicates that BME is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.1
BME Yearly Current Assets VS Current LiabilitesBME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BME Growth Analysis

3.1 Past

  • The earnings per share for BME have decreased strongly by -150.26% in the last year.
  • BME shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.80% yearly.
  • BME shows a decrease in Revenue. In the last year, the revenue decreased by -6.58%.
  • The Revenue has been growing by 8.91% on average over the past years. This is quite good.
EPS 1Y (TTM)-150.26%
EPS 3Y-26.89%
EPS 5Y-24.8%
EPS Q2Q%-108.48%
Revenue 1Y (TTM)-6.58%
Revenue growth 3Y5.76%
Revenue growth 5Y8.91%
Sales Q2Q%-2.46%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BME Yearly Revenue VS EstimatesBME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

Find the best growth stocksShow best growing peers

0

4. BME Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BME. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BME Price Earnings VS Forward Price EarningsBME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 6.42
EV/EBITDA N/A
BME Per share dataBME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. BME Dividend Analysis

5.1 Amount

  • BME has a Yearly Dividend Yield of 6.99%, which is a nice return.
  • Compared to an average S&P500 Dividend Yield of 1.82, BME pays a better dividend.
Industry RankSector Rank
Dividend Yield 6.99%

5.2 History

  • The dividend of BME has a limited annual growth rate of 3.39%.
  • BME has paid a dividend for at least 10 years, which is a reliable track record.
  • BME has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)3.39%
Div Incr Years1
Div Non Decr Years10
BME Yearly Dividends per shareBME Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3

5.3 Sustainability

  • The earnings of BME are negative and hence is the payout ratio. BME will probably not be able to sustain this dividend level.
DP-148.67%
EPS Next 2YN/A
EPS Next 3YN/A
BME Yearly Income VS Free CF VS DividendBME Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

More info and screens

Find the best dividend stocksShow peers with best dividend

BME Fundamentals: All Metrics, Ratios and Statistics

BLACKROCK HEALTH SCIENCES

NYSE:BME (3/9/2026, 1:42:11 PM)

40.73

-0.52 (-1.26%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)03-05
Earnings (Next)N/A
Inst Owners21.62%
Inst Owner Change136.17%
Ins Owners0%
Ins Owner Change0%
Market Cap526.23M
Revenue(TTM)7.47M
Net Income(TTM)-25.56M
Analysts0
Price TargetN/A
Short Float %0.56%
Short Ratio1.92
Dividend
Industry RankSector Rank
Dividend Yield 6.99%
Yearly Dividend2.67
Dividend Growth(5Y)3.39%
DP-148.67%
Div Incr Years1
Div Non Decr Years10
Ex-Date06-15
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 70.45
P/FCF 6.42
P/OCF 6.42
P/B 1.04
P/tB 1.04
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)6.35
FCFY15.58%
OCF(TTM)6.35
OCFY15.58%
SpS0.58
BVpS39.32
TBVpS39.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.83%
ROE -5.03%
ROCE 0.2%
ROIC 0.16%
ROICexc 0.16%
ROICexgc 0.16%
OM 13.92%
PM (TTM) N/A
GM 100%
FCFM 1097.72%
ROA(3y)1.06%
ROA(5y)5.33%
ROE(3y)1.07%
ROE(5y)5.44%
ROIC(3y)0.2%
ROIC(5y)0.12%
ROICexc(3y)0.2%
ROICexc(5y)0.12%
ROICexgc(3y)0.2%
ROICexgc(5y)0.12%
ROCE(3y)0.25%
ROCE(5y)0.16%
ROICexgc growth 3Y199.74%
ROICexgc growth 5Y4.01%
ROICexc growth 3Y199.74%
ROICexc growth 5Y4.01%
OM growth 3Y169.88%
OM growth 5Y-0.74%
PM growth 3Y-30.97%
PM growth 5Y-28.42%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.02
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.1
Altman-Z 15.59
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-150.26%
EPS 3Y-26.89%
EPS 5Y-24.8%
EPS Q2Q%-108.48%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.58%
Revenue growth 3Y5.76%
Revenue growth 5Y8.91%
Sales Q2Q%-2.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-38.46%
EBIT growth 3Y185.41%
EBIT growth 5Y8.1%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y432.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y432.12%
OCF growth 3YN/A
OCF growth 5YN/A

BLACKROCK HEALTH SCIENCES / BME FAQ

What is the fundamental rating for BME stock?

ChartMill assigns a fundamental rating of 2 / 10 to BME.


What is the valuation status for BME stock?

ChartMill assigns a valuation rating of 0 / 10 to BLACKROCK HEALTH SCIENCES (BME). This can be considered as Overvalued.


How profitable is BLACKROCK HEALTH SCIENCES (BME) stock?

BLACKROCK HEALTH SCIENCES (BME) has a profitability rating of 1 / 10.


What is the financial health of BLACKROCK HEALTH SCIENCES (BME) stock?

The financial health rating of BLACKROCK HEALTH SCIENCES (BME) is 3 / 10.


Can you provide the dividend sustainability for BME stock?

The dividend rating of BLACKROCK HEALTH SCIENCES (BME) is 5 / 10 and the dividend payout ratio is -148.67%.